A new look at triple-negative breast cancer

By Jan Jarvis

Breast Cancer

Triple-negative breast cancer (TNBC) is often aggressive, hard to treat and disproportionately affects carriers of the BRCA1 gene mutation and younger women of African origin.

Researchers at UNT Health Science Center have received a $1.9 million grant from the National Cancer Institute to help develop a new therapy that holds promise for the 38,000 to 55,000 women who are diagnosed with this disease each year.

Jamboor K Vishwanatha, PhD, and his colleagues – Pankaj Chaudhary, PhD, and Sumihiro Suzuki, PhD – will measure a protein called Annexin A2, which is shed from cancer cells and circulates in the blood.  This protein leads to the aggressiveness of triple-negative breast cancer and its metastasis to other organs, said Dr.Vishwanatha, Regents Professor and Vice President for Diversity and International Programs.

“Our research could potentially lead to a biomarker that can predict aggressive TNBC metastasis in African-American women, and possibly lead to development of new therapeutic options for women with this type of breast cancer,” Dr. Vishwanatha said.

About 15 percent to 20 percent of breast cancers are triple-negative. This means that three common receptors known to fuel most breast cancer growth – estrogen, progesterone, and the HER-2/neu gene – are not present in the tumor. As a result, common treatments like hormone therapy and drugs that target estrogen, progesterone, and HER-2 are ineffective.

Triple-negative breast cancer is prevalent in women who carry a mutated copy of the BRCA1 gene and in women of African descent. Those who are diagnosed with TNBC have a high frequency of metastasis to the lung, liver and brain, and survival is generally poor.

African-American women with TNBC tend to have worse clinical outcomes compared with women of European descent who have the disease. The disease is often more aggressive in African-American women.

The research could lead to better treatments for those who are disproportionately affected by this disease, said Dr. Chaudhary, Research Assistant Professor in the Institute of Molecular Medicine.

“We predict the results arising from the proposed studies will lay the foundation for future studies to determine if circulating levels of Annexin A2 need to be taken into consideration during study design in metastasis detection, prognosis, and therapy for African-American patients with TNBC,” Dr. Chaudhary said.

Dr. Suzuki, Associate Professor and Chair of Biostatistics and Epidemiology in the School of Public Health, will oversee data management, data cleaning and preparation, and data analyses.

To conduct this project, Dr. Vishwanatha is working with collaborators from across the country and around the world, including 14 institutions in Africa and Europe.

Recent News

Processed With Lensa With Pt12 Filter
  • Research
|Mar 28, 2024

Dr. Steven Romero receives American Physiological Society award for excellence in research

Dr. Steven Romero, associate professor of Physiology and Anatomy at the School of Biomedical Sciences at The University of North Texas Health Science Center at Fort Worth, was named the 2024 Henry Pickering Bowditch Award Lecturer by the American Physiological Society. The lectureship is awarded to ...
Screenshot 2024 03 28 At 8.50.12 am
  • Our People
|Mar 28, 2024

Physical therapy student lands prestigious role in national organization

When Jonathan Hansen was an undergraduate intern at Texas Health Arlington Memorial Hospital, he encountered a man who had just suffered a stroke. The patient’s right side was completely paralyzed. Hansen, now a first-year student in The University of North Texas Health Science Center at Fort Wort...
Jackie In Dc
  • Our People
|Mar 27, 2024

Personalized Health and Well-Being student repays generosity through advocacy

In 2019, The University of North Texas Health Science Center at Fort Worth student Jacqueline Green said she felt hopeless. She became pregnant while experiencing hard financial times, and she didn’t have insurance. Compounding her stress was terrible grief. Her mother-in-law suddenly passed away,...
Image1 3
  • Our People
|Mar 26, 2024

The first licensed DO in Chile is a TCOM graduate and an unlikely osteopathic physician

If you’re looking for the unlikeliest of people to practice osteopathic medicine, osteopathy, or osteopathic manipulative treatment then look no further than Patrick Wedlake, DO. So, how did a self-described “hippie from California,” end up becoming the first licensed osteopathic physician in ...